

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

PATENT



Applicant: L. Alani, et al.

Serial No.: 09/576,097

Filed: May 22, 2000

For: IMPROVED PHARMACEUTICAL FORMULATIONS

Examiner: D. Lukton

Group Art Unit: 1653

Docket No.: 6499.US.02

Certificate of Mailing (37 C.F.R. 1.8(a))

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents  
Washington, D. C. 20231, on:

Date of Deposit: May 17, 2002

*Wanda E. Smith* 5/17/02  
Wanda E. Smith Date

Date: May 17, 2002

AMENDMENT AND RESPONSE

Commissioner for Patents  
Washington, D.C. 20231

**RECEIVED**

MAY 28 2002

Dear Sir:

TECH CENTER 1600/2900

Please amend this application as follows:

**IN THE CLAIMS:**

Please cancel, without prejudice to the patentability thereof, Claims 2, 12 and 13.

*91*

1. (amended) A pharmaceutical composition comprising:
  - (a) solubilized ritonavir or a combination of solubilized ritonavir and another HIV protease inhibiting compound, or pharmaceutically acceptable salts thereof, in the amount of from about 1% to about 50% by weight of the total solution;
  - (b) a pharmaceutically acceptable organic solvent which comprises a medium and/or long chain fatty acid or a mixture thereof in the amount of from about 40% to about 75% by weight of the total solution, and ethanol or propylene glycol in the amount of from about 1% to about 15% by weight of the total solution;
  - (c) water in the amount of from about 0.4% to about 3.5% by weight of the total solution; and
  - (d) optionally, a pharmaceutically acceptable surfactant.